Intensity Therapeutics (NASDAQ:INTS – Get Free Report) is one of 610 public companies in the “MED – BIOMED/GENE” industry, but how does it contrast to its rivals? We will compare Intensity Therapeutics to related companies based on the strength of its institutional ownership, profitability, earnings, valuation, analyst recommendations, dividends and risk.
Risk & Volatility
Intensity Therapeutics has a beta of 2.77, suggesting that its stock price is 177% more volatile than the S&P 500. Comparatively, Intensity Therapeutics’ rivals have a beta of 1.10, suggesting that their average stock price is 10% more volatile than the S&P 500.
Profitability
This table compares Intensity Therapeutics and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Intensity Therapeutics | N/A | -136.82% | -105.82% |
| Intensity Therapeutics Competitors | -809.34% | -698.29% | -27.91% |
Valuation & Earnings
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Intensity Therapeutics | N/A | -$11.61 million | -0.63 |
| Intensity Therapeutics Competitors | $853.73 million | $65.75 million | -28.34 |
Intensity Therapeutics’ rivals have higher revenue and earnings than Intensity Therapeutics. Intensity Therapeutics is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
3.7% of Intensity Therapeutics shares are held by institutional investors. Comparatively, 51.3% of shares of all “MED – BIOMED/GENE” companies are held by institutional investors. 7.1% of Intensity Therapeutics shares are held by insiders. Comparatively, 12.3% of shares of all “MED – BIOMED/GENE” companies are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
Analyst Ratings
This is a summary of recent ratings and target prices for Intensity Therapeutics and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Intensity Therapeutics | 1 | 0 | 2 | 1 | 2.75 |
| Intensity Therapeutics Competitors | 8650 | 13327 | 40678 | 1404 | 2.54 |
Intensity Therapeutics presently has a consensus price target of $37.50, suggesting a potential upside of 935.91%. As a group, “MED – BIOMED/GENE” companies have a potential upside of 63.97%. Given Intensity Therapeutics’ stronger consensus rating and higher probable upside, analysts plainly believe Intensity Therapeutics is more favorable than its rivals.
Summary
Intensity Therapeutics beats its rivals on 7 of the 13 factors compared.
Intensity Therapeutics Company Profile
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Receive News & Ratings for Intensity Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intensity Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
